GS-9620 is a potent and selective oral Toll-like receptor 7 (TLR7) agonist that directly activates plasmacytoid dendritic cells (pDCs). GS-9620 suppressed hepatitis B virus (HBV) in animal models of chronic infection and transiently activated HIV expressionex vivoin latently-infected peripheral blood mononuclear cells (PBMCs) from virally suppressed patients. Currently, GS-9620 is under clinical evaluation for treating chronic HBV infection and for reducing latent reservoirs in virally-suppressed HIV-infected patients.
Lopatin, U, et al. "Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist." Antiviral Therapy18.3(2013):409-18.
Gane, E. J., et al. "The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection." Journal of Hepatology63.2(2015):320.
Lanford, Robert E., et al. "GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees." Gastroenterology 144.7(2013):1508.
